Stock Events

Stock Events

Yumanity Therapeutics

$4.95

12

+$3.06+161.9% Monday 21:00

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Dividends

0%Dividend Yield

Dec 22

$1.43

Dec 22

$1.43

10Y Growth

N/A

5Y Growth

N/A

3Y Growth

N/A

1Y Growth

N/A

Earnings

28MarExpected

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Q3 2024

Q4 2024

-0.89

-0.58

-0.27

0.04

Expected EPS

-0.24

Actual EPS

N/A

Financials

-491.15%Profit Margin

Unprofitable

2020

2021

8.04MRevenue

-39.5MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow YMTX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Merck & Co., Inc. is a global healthcare company that develops medications and vaccines across various areas, including those that Kineta is involved in, making them direct competitors in the pharmaceutical and biotech space.

Pfizer Inc. operates in the same biopharmaceutical field as Kineta, focusing on the discovery, development, and manufacture of healthcare products including medicines and vaccines.

Bristol-Myers Squibb

Bristol-Myers Squibb Company is a competitor due to its engagement in the discovery, development, and marketing of prescription pharmaceuticals in areas overlapping with Kineta's interests.

Gilead Sciences

Gilead Sciences, Inc. competes with Kineta in the biopharmaceutical sector, particularly in the development and marketing of antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza.

Amgen Inc. is a biotechnology company that competes with Kineta by focusing on areas such as oncology/hematology, cardiovascular disease, and inflammation.

AbbVie Inc. operates in the same pharmaceutical and biotechnology industry as Kineta, with a focus on immunology, oncology, and virology, among others.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company that competes with Kineta in developing and commercializing medicines for the treatment of serious medical conditions.

Novartis AG is a global healthcare company that competes with Kineta in researching, developing, manufacturing, and marketing a wide range of healthcare products.

Johnson & Johnson

Johnson & Johnson is a diverse healthcare company that competes with Kineta through its pharmaceutical segment, which develops and markets drugs in various therapeutic areas.

AstraZeneca PLC is a biopharmaceutical company that competes with Kineta in the development and commercialization of prescription medicines, including those for several diseases that Kineta targets.

About

Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.

Show more...

CEO

Meenu Chhabra

Employees

11

Country

United States

ISIN

US98872L1026

WKN

000A3D2GA

Listings

0 Comments

Share your thoughts

FAQ

What is Yumanity Therapeutics stock price today?▼

The current price of YMTX is $4.95 USD — it has increased by +161.9% in the past 24 hours. Watch Yumanity Therapeutics stock price performance more closely on the chart.

What is Yumanity Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Yumanity Therapeutics stocks are traded under the ticker YMTX.

What is Yumanity Therapeutics revenue for the last year?▼

Yumanity Therapeutics revenue for the last year amounts to 8.04M USD.

What is Yumanity Therapeutics net income for the last year?▼

YMTX net income for the last year is -39.5M USD.

Does Yumanity Therapeutics pay dividends?▼

Yes, YMTX dividends are paid en. The last dividend per share was 1.43 USD. As of today, Dividend Yield (FWD)% is 0%.

How many employees does Yumanity Therapeutics have?▼

As of April 13, 2026, the company has 11 employees.

In which sector is Yumanity Therapeutics located?▼

Yumanity Therapeutics operates in the Technology sector.

When did Yumanity Therapeutics complete a stock split?▼

The last stock split for Yumanity Therapeutics was on December 23, 2020 with a ratio of 1:20.

Where is Yumanity Therapeutics headquartered?▼

Yumanity Therapeutics is headquartered in Boston, United States.